

OPEN TO ENROLLMENT Protocol	Status	Ages	Inclusion / Exclusion
<p>Sponsor/Study Name SK Life/ “A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures”</p> <p>YKP3089CO25</p> <p>PI – Dr Segal- PEDS / Sub-I Dr Rafiuddin-Adults XCOPRI</p>	OPEN To Enrollment	12-60yr	<ul style="list-style-type: none"> ✓DX PGTC seizures ✓Must have 5 PGTC seizures 12 weeks prior to baseline ✓May be on 1 to 3 AEDS ✓VNS must be implanted a least 5 months prior to baseline ✓Excluded if they also have POS seizures or LGS DX
<p>Sponsor/Study Name SK Life/A phase 1, open label pharmacokinetic dose escalation study of Cenobamate (YKP3089) in Pediatric Subjects with POS. YKP3089C039</p> <p>PI – Dr Segal- PEDS XCOPRI</p>	OPEN To Enrollment	12-18 Cohort 1 6-<12 Cohort 2 4-<6 Cohort 3 2-<4 Cohort 4	<ul style="list-style-type: none"> ✓ DX POS ✓ Failed 2 previous AEDs ✓ May be on 1 to 3 AEDS ✓ If on Onfi must be off a least 30 days prior to Day 1 ✓ Offsite for in unit PKs draws from Day -1 - Day 4.
<p>Sponsor/Study Name: SK Life/” A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults, with Optional Open-Label Extension”</p> <p>YKP509 -- YKP509CO03</p> <p>PI – Dr Segal / Sub-I Dr Rafiuddin CARISBAMATE</p>	OPEN To Enrollment	4-55 yr.	<ul style="list-style-type: none"> ✓Documented HX of LGS ✓Must have evidence of more than one type of seizure ✓One of those seizure types must be either drop (atonic / tonic) or tonic-clonic seizures 6 months prior to baseline ✓Drop seizures must have 2 with the potential to fall or tonic clonic seizures per week during the 4 wk baseline period ✓Onset of LGS must be < 11 yrs. old May be on 1 to 4 AEDS

PENDING STUDIES

PENDING Protocol	Status	Ages	Inclusion / Exclusion
<p>Sponsor/Study Name: SK Life/ “Open-Label Safety and Efficacy Study of Cenbamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures” YKP3089C040 PI – Dr Segal XCOPRI</p>	<p>PENDING October</p>	<p>2-17 yr.</p>	<ul style="list-style-type: none"> ✓DX with POS (Focal) ✓May be on 1 to 3 AEDS ✓Must have one POS within 8 weeks prior to baseline
<p>Sponsor/Study Name: Equilibre/A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures EQU-202 PI – Dr Rafiuddin-Adults /Sub -I Dr Segal-PEDS IVERMECTIN</p>	<p>PENDING 4th Quater</p>	<p>16-65yr</p>	<ul style="list-style-type: none"> ✓DX with POS (Focal). May not include focal aware seizures without a detectable motor component, aphasia or other observable symptom. ✓May be on 1 to 3 AEDS ✓Must have 4 countable Focal seizures a month
<p>Sponsor/Study Name: Marinus_Pharmaceuticals/ A phase 3,double blind randomized placebo controlled trial of adjunctive Ganaxolone (GNX) treatment in children and Adults with Tuberous Sclerosis Complex(TSC) related Epilepsy (TRUSTTSC)1042-TSC-3001 PI – Dr Rafiuddin-Adults /Sub -I Dr Segal-PEDS</p>	<p>SIV August 9th Open for enrollment August 10th</p>	<p>1-65yr</p>	<p>Clinical or mutational diagnosis of TSC</p> <ul style="list-style-type: none"> ✓ Molecular confirmation or clinical diagnosis ✓ Failed a least 2 AEDs ✓ 8 countable seizures per month in the 2 months before screening
<p>Sponsor/Study Name: Xenon Pharmaceuticals / A Randomized, Double-Blind Placebo-controlled multicenter Phase 3 Study to Evaluate the safety tolerability and efficacy of XEN1101 as adjunctive Therapy in focal -onset Epilepsy XPF-008-301 PI – Dr Rafiuddin-Adults</p>	<p>Pending late August/Early September</p>	<p>18-75yr</p>	<ul style="list-style-type: none"> ✓ DX with POS (Focal) ✓ HX of only focal aware without motor seizures only will not be allowed ✓ May be on 1 to 3 AEDS ✓ During the 8-week baseline period must have more than 4 focal seizures within 28 days
<p>Sponsor/Study Name Engrail Therapeutics /_Randomized double-blind placebo controlled adjunctive treatment trial to evaluate the efficacy and safety of _ENX -101 -005 in patients with treatment refractory Focal (POS) seizures ENX-101-005 PI – Dr Rafiuddin-Adults</p>	<p>September</p>	<p>18-75yr</p>	<ul style="list-style-type: none"> ✓ DX with POS (Focal) ✓ HX of only focal aware without motor seizures only will not be allowed ✓ May be on 1 to 4 AEDS ✓ 3 months prior to screening must have between ≥ 3 observable focal seizures with no more than ≤10 in a day in a 28-day period (9-30 seizures in 3 months) ✓ During the 8-week baseline (screening →Day 1) ≥6 observable focal seizures with no more than ≤10 in a day